ALLO · Insider Trading
Allogene Therapeutics, Inc. Common Stock
Every open-market purchase and sale reported by ALLO officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-23 | Geoffrey M. Parker | CHIEF FINANCIAL OFFICER | Sell | −36,342 | −$48.70K |
| 2026-08-25 | Earl Martin Douglas | SVP, General Counsel | Sell | −29,697 | −$62.96K |
| 2026-07-06 | Zachary Roberts | President and CEO | A | +610,720 deriv. | — |
| 2026-06-23 | Vicki L Sato | Director | A | +95,400 deriv. | — |
| 2026-06-23 | Franz B Humer | Director | A | +95,400 deriv. | — |
| 2026-06-23 | Stephen Mayo | Director | A | +144,400 deriv. | — |
| 2026-06-23 | Joshua A Kazam | Director | M | +47,700 | — |
| 2026-06-23 | Elizabeth A. Barrett | Director | A | +95,400 deriv. | — |
| 2026-06-23 | Deborah M. Messemer | Director | A | +95,400 deriv. | — |
| 2026-06-23 | Owen N. Witte | Director | A | +95,400 deriv. | — |
| 2026-04-23 | Annie Yoshiyama | SVP, Finance | Sell | −9,586 | −$22.14K |
| 2026-04-02 | Benjamin Machinas Beneski | SVP, Chief Technical Officer | Sell | −2,867 | −$7.17K |
| 2026-03-18 | Benjamin Machinas Beneski | SVP, Chief Technical Officer | Sell | −4,835 | −$11.94K |
| 2026-03-18 | David D Chang | President and CEO | Sell | −47,763 | −$117.97K |
| 2026-03-04 | Benjamin Machinas Beneski | SVP, Chief Technical Officer | Sell | −7,132 | −$18.54K |
| 2026-02-04 | Geoffrey M. Parker | CHIEF FINANCIAL OFFICER | Sell | −24,001 | −$42.24K |
| 2026-02-04 | Zachary Roberts | EVP of R&D | Sell | −35,700 | −$63.19K |
| 2026-02-04 | Annie Yoshiyama | SVP, Finance | Sell | −4,167 | −$7.17K |
| 2026-02-04 | Benjamin Machinas Beneski | SVP, Chief Technical Officer | Sell | −7,549 | −$13.06K |
| 2026-02-04 | David D Chang | President and CEO | Sell | −95,269 | −$171.48K |
| 2026-02-04 | Arie Belldegrun | Director | A | — | — |
| 2026-02-04 | Earl Martin Douglas | SVP, General Counsel | Sell | −22,900 | −$40.30K |
| 2026-01-23 | Zachary Roberts | EVP of R&D | Sell | −26,269 | −$40.98K |
| 2025-12-22 | Joshua A Kazam | Director | M | +47,700 | — |
| 2025-11-19 | Benjamin Machinas Beneski | SVP, Chief Technical Officer | Sell | −786 | −$959 |
| 2025-10-23 | Geoffrey M. Parker | CHIEF FINANCIAL OFFICER | Sell | −36,744 | −$46.17K |
| 2025-06-23 | Stephen Mayo | Director | A | +95,400 deriv. | — |
| 2025-06-23 | Elizabeth A. Barrett | Director | A | +95,400 deriv. | — |
| 2025-06-23 | Owen N. Witte | Director | A | +95,400 deriv. | — |
| 2025-06-23 | Vicki L Sato | Director | A | +144,400 deriv. | — |
| 2025-06-23 | Deborah M. Messemer | Director | A | +95,400 deriv. | — |
| 2025-06-23 | Joshua A Kazam | Director | A | +94,500 deriv. | — |
| 2025-06-23 | Franz B Humer | Director | A | +95,400 deriv. | — |
| 2025-06-12 | Deborah M. Messemer | Director | Sell | −36,885 | −$52.38K |
| 2025-04-23 | Annie Yoshiyama | SVP, Finance | Sell | −9,601 | −$13.54K |
| 2025-03-18 | David D Chang | President and CEO | Sell | −46,668 | −$91.47K |
| 2025-03-18 | Benjamin Machinas Beneski | SVP, Chief Technical Officer | Sell | −5,488 | −$10.84K |
| 2025-03-05 | Benjamin Machinas Beneski | SVP, Chief Technical Officer | A | +31,755 | — |
| 2025-02-20 | Deborah M. Messemer | Director | Sell | −13,313 | −$32.35K |
| 2025-02-05 | Timothy L. Moore | Chief Technical Officer | Sell | −14,746 | −$25.22K |
| 2025-02-05 | Geoffrey M. Parker | CHIEF FINANCIAL OFFICER | Sell | −4,361 | −$7.54K |
| 2025-02-05 | Zachary Roberts | EVP of R&D | Sell | −18,832 | −$32.01K |
| 2025-02-05 | Earl Martin Douglas | SVP, General Counsel | Sell | −6,404 | −$10.95K |
| 2025-02-05 | David D Chang | President and CEO | Sell | −46,003 | −$77.29K |
| 2025-01-28 | Geoffrey M. Parker | CHIEF FINANCIAL OFFICER | A | +173,913 | — |
| 2025-01-28 | Annie Yoshiyama | SVP, Finance | A | +36,232 | — |
| 2025-01-28 | Zachary Roberts | EVP of R&D | A | +173,913 | — |
| 2025-01-28 | Earl Martin Douglas | SVP, General Counsel | A | +144,928 | — |
| 2025-01-28 | David D Chang | President and CEO | A | +552,174 | — |
| 2025-01-28 | Arie Belldegrun | Director | A | +369,957 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| David D Chang | President and CEO | 6,006,643 | $7.27M |
| Arie Belldegrun | Director | 4,034,979 | $4.88M |
| Geoffrey M. Parker | CHIEF FINANCIAL OFFICER | 1,045,877 | $1.27M |
| Zachary Roberts | President and CEO | 581,166 | $703.21K |
| Earl Martin Douglas | SVP, General Counsel | 488,267 | $590.80K |
| Joshua A Kazam | Director | 398,463 | $482.14K |
| Franz B Humer | Director | 307,507 | $372.08K |
| Owen N. Witte | Director | 292,832 | $354.33K |
| Timothy L. Moore | Chief Technical Officer | 250,713 | $303.36K |
| Benjamin Machinas Beneski | SVP, Chief Technical Officer | 195,338 | $236.36K |
| Vicki L Sato | Director | 162,575 | $196.72K |
| Annie Yoshiyama | SVP, Finance | 124,517 | $150.67K |
| Deborah M. Messemer | Director | 113,966 | $137.90K |
| Stephen Mayo | Director | 25,328 | $30.65K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ALLO quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.